CTXR RSI Chart
Last 7 days
-4.3%
Last 30 days
-10.7%
Last 90 days
-16.2%
Trailing 12 Months
-39.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2014 | 34.6K | 29.3K | 0 | 0 |
2013 | 22.1K | 18.7K | 29.1K | 0 |
2012 | 12.6K | 12.9K | 15.6K | 0 |
2011 | 0 | 0 | 13.4K | 7.6K |
2010 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 27, 2019 | holubiak myron z | bought | 500,000 | 0.8951 | 558,597 | president and ceo |
Sep 27, 2019 | mazur leonard l | bought | 2,000,280 | 0.8951 | 2,234,700 | executive chairman |
Apr 03, 2019 | holubiak myron z | bought | 200,000 | 1.545 | 129,450 | president and ceo |
Apr 03, 2019 | mazur leonard l | bought | 1,800,000 | 1.545 | 1,165,050 | executive chairman |
Which funds bought or sold CTXR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -20.51 | -4,269 | 70,392 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -33.15 | -3,168 | 12,134 | -% |
May 15, 2024 | Kestra Advisory Services, LLC | added | 11.69 | 17,794 | 72,582 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -92.34 | -27,000 | 3,000 | -% |
May 15, 2024 | Voya Investment Management LLC | reduced | -7.69 | 3,726 | 42,971 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -23,877 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -37.82 | -2,625 | 7,349 | -% |
May 15, 2024 | BARCLAYS PLC | reduced | -44.04 | -43,000 | 85,000 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -71.1 | -89,727 | 46,819 | -% |
May 15, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 7.47 | 6,000 | 28,000 | -% |
Unveiling Citius Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Citius Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.22 | 9.73 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.57 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Citius Pharmaceuticals Inc News
Income Statement (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2014Q2 | 2014Q1 | 2013Q3 | 2013Q2 | 2013Q1 | 2012Q3 | 2012Q2 | 2012Q1 | 2011Q4 | 2011Q3 | 2011Q2 | 2011Q1 | 2010Q4 | 2010Q3 |
Revenue | -64.2% | 3,360 | 9,396 | 13,375 | 3,200 | 8,650 | 3,906 | 2,950 | 6,573 | 2,130 | 1,250 | 2,600 | 1,600 | 8,000 | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -6.9% | 91.00 | 97.00 | 104 | 110 | 104 | 112 | 114 | 120 | 128 | 138 | 142 | 147 | 135 | 35.00 | 44.00 | 38.00 | 26.00 | 25.00 | 37.00 | 26.00 | 24.00 |
Current Assets | -23.5% | 22.00 | 28.00 | 34.00 | 41.00 | 35.00 | 42.00 | 45.00 | 51.00 | 58.00 | 68.00 | 73.00 | 117 | 105 | 6.00 | 14.00 | 9.00 | 4.00 | 3.00 | 8.00 | 5.00 | 3.00 |
Cash Equivalents | -38.3% | 13.00 | 20.00 | 26.00 | 33.00 | 29.00 | 37.00 | 42.00 | 48.00 | 56.00 | 65.00 | 70.00 | 116 | 104 | 4.00 | 14.00 | 9.00 | 4.00 | 3.00 | 8.00 | 5.00 | 3.00 |
Net PPE | -67.8% | 275* | 854* | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 236* | 413* | 590* | 777* | 0.00 |
Goodwill | 0% | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 2.00 | 2.00 | 9.00 | 2.00 | 2.00 |
Liabilities | -10.9% | 11.00 | 12.00 | 12.00 | 12.00 | 12.00 | 11.00 | 11.00 | 10.00 | 10.00 | 13.00 | 10.00 | 9.00 | 9.00 | 10.00 | 10.00 | 10.00 | 4.00 | 5.00 | 10.00 | - | - |
Current Liabilities | -25.2% | 4.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.00 | 7.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 5.00 | 4.00 | 3.00 |
Shareholder's Equity | -5.6% | 80.00 | 85.00 | 91.00 | 98.00 | 92.00 | 101 | 103 | 110 | 118 | 125 | 133 | 137 | 126 | 26.00 | 34.00 | 29.00 | 25.00 | 23.00 | 27.00 | 24.00 | 24.00 |
Retained Earnings | -5.0% | -180 | -171 | -162 | -152 | -143 | -133 | -129 | -121 | -112 | -105 | -96.05 | -91.09 | -85.26 | -81.14 | -70.59 | -66.47 | -64.57 | -60.14 | -53.05 | -52.17 | -47.76 |
Additional Paid-In Capital | 1.2% | 259 | 256 | 253 | 250 | 235 | 234 | 232 | 231 | 230 | 229 | 228 | 228 | 210 | 106 | 104 | 95.00 | 87.00 | 80.00 | 80.00 | 74.00 | 69.00 |
Shares Outstanding | 0.1% | 159 | 159 | 159 | 159 | 146 | 146 | 146 | 146 | 146 | 146 | 146 | 96.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | - | 157 | - | - | - | 240 | - | - | - | 218 | - | - | - | 16.00 | - | - | - | 9.00 |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -26.9% | -7,786 | -6,135 | -6,800 | -9,582 | -7,853 | -4,824 | -6,332 | -7,712 | -9,665 | -4,651 | -5,591 | -4,823 | -4,271 | -9,564 | -3,357 | -3,991 | -4,467 | -5,114 | -2,907 | -3,522 | -3,849 |
Share Based Compensation | 0.7% | 3,078 | 3,058 | 3,076 | 1,174 | 1,166 | 1,201 | 977 | 1,004 | 1,021 | 905 | 462 | 374 | 343 | 277 | 249 | 175 | 159 | 220 | 137 | 204 | 204 |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | - | - | -40,000 | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | - | - | - | -687* | 13,799 | - | - | - | - | - | - | - | 16,797 | 103,673 | 500* | 8,700 | 8,171 | 6,027 | 106* | 6,290 | 4,834 | 7.00 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||||
Revenues | ||||
Operating Expenses | ||||
Research and development | 3,605,898 | 4,726,855 | $ 6,227,808 | $ 8,172,370 |
General and administrative | 4,285,911 | 4,792,850 | 7,946,639 | 7,396,137 |
Stock-based compensation – general and administrative | 3,078,392 | 1,165,595 | 6,136,577 | 2,366,676 |
Total Operating Expenses | 10,970,201 | 10,685,300 | 20,311,024 | 17,935,183 |
Operating Loss | (10,970,201) | (10,685,300) | (20,311,024) | (17,935,183) |
Other Income | ||||
Interest income | 182,205 | 303,275 | 435,843 | 517,824 |
Gain on sale of New Jersey net operating losses | 2,387,842 | 2,387,842 | 3,585,689 | |
Total Other Income | 2,570,047 | 303,275 | 2,823,685 | 4,103,513 |
Loss before Income Taxes | (8,400,154) | (10,382,025) | (17,487,339) | (13,831,670) |
Income tax expense | 144,000 | 144,000 | 288,000 | 288,000 |
Net Loss | $ (8,544,154) | $ (10,526,025) | $ (17,775,339) | $ (14,119,670) |
Net Loss Per Share - Basic (in Dollars per share) | $ (0.05) | $ (0.07) | $ (0.11) | $ (0.1) |
Weighted Average Common Shares Outstanding | ||||
Weighted Average Common Shares Outstanding, Basic (in Shares) | 159,072,239 | 146,251,945 | 159,013,769 | 146,231,313 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Sep. 30, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 12,559,607 | $ 26,480,928 |
Prepaid expenses | 9,014,124 | 7,889,506 |
Total Current Assets | 21,573,731 | 34,370,434 |
Property and equipment, net | 275 | 1,432 |
Operating lease right-of-use asset, net | 352,505 | 454,426 |
Deposits | 38,062 | 38,062 |
In-process research and development | 59,400,000 | 59,400,000 |
Goodwill | 9,346,796 | 9,346,796 |
Total Assets | 90,711,369 | 103,611,150 |
Current Liabilities: | ||
Accounts payable | 2,669,507 | 2,927,334 |
Accrued expenses | 151,204 | 476,300 |
Accrued compensation | 1,123,076 | 2,156,983 |
Operating lease liability | 229,733 | 218,380 |
Total Current Liabilities | 4,173,520 | 5,778,997 |
Deferred tax liability | 6,425,800 | 6,137,800 |
Operating lease liability – noncurrent | 145,098 | 262,865 |
Total Liabilities | 10,744,418 | 12,179,662 |
Commitments and Contingencies | ||
Stockholders’ Equity: | ||
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding | ||
Common stock – $0.001 par value; 400,000,000 shares authorized; 159,094,781 and 158,857,798 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively | 159,095 | 158,858 |
Additional paid-in capital | 259,214,194 | 252,903,629 |
Accumulated deficit | (180,006,718) | (162,231,379) |
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity | 79,366,571 | 90,831,108 |
Non-controlling interest | 600,380 | 600,380 |
Total Equity | 79,966,951 | 91,431,488 |
Total Liabilities and Equity | $ 90,711,369 | $ 103,611,150 |